Mr. Kevin R. Lind has been the Chief Financial Officer and Executive Vice President at Arena Pharmaceuticals, Inc. since June 15, 2016. Mr. Lind served as the Principal Accounting Officer at Arena Pharmaceuticals, Inc. since August 10, 2016. He has with over 15 years of experience in healthcare banking and private equity. Mr. Lind is lead underwriter of TOP’s Life Sciences structured investments and drug royalty monetizations effort. Mr. Lind was the Vice President at TPG Biotech. Prior to Arena, Mr. Lind was at TPG, as a Principal at TPG Special Situations Partners and initially at TPG-Axon'sPharma Partners group. Mr. Lind was instrumental in the structured and royalty effort at TPG-Axon. Mr. Lind was a Member of the TPG Pharma Partners effort at TPG-Axon from 2006 to 2008. Prior to joining TPG-Axon in 2006, Mr. Lind held over five years of experience in Lehman Brothers' Healthcare Investment Banking group, starting in 1998. where he completed over 20 mergers and acquisitions, partnering agreements and financings for life sciences and medical device companies. Mr. Lind is a Board Observer of Edev S.à.r.l. He was a JDC observer for a structured investment at TPG-Axon. Mr. Lind received an M.B.A. from UCLA Anderson School of Management and a B.S. in Biological Sciences from Stanford University

Bussiness development